Midterm results of the Birmingham hip resurfacing: a single-surgeon series

Arch Orthop Trauma Surg. 2023 Feb;143(2):1041-1048. doi: 10.1007/s00402-021-04305-0. Epub 2022 Jan 25.

Abstract

Introduction: Birmingham hip resurfacing (BHR) is readily used as alternative to total hip replacement in younger patients. The current study aims to compare outcomes in terms of adverse local tissue reactions (ALTR), elevated metal ion levels and survival rates between low-risk (femoral component size ≥ 48 mm) and high-risk (femoral component size < 48 mm) BHR patients at a minimum 5-year follow-up (FU).

Materials and methods: We report the minimum 5-year, single surgeon outcome results of 183 BHRs, performed between 2007 and 2012. 154 patients, 18 women (20 hips) and 136 men (163 hips) were included in the study. Patients were grouped in 149 low-risk cases (femoral component size ≥ 48 mm) and in 34 high-risk cases (18 female/12 male) patients with a femoral head size < 48 mm).

Results: At a minimum of 5-years FU time, 91% of the patients were available for FU. The overall survival rate was 91.8%. There were five revisions (survival rate 96.6%) in the low-risk group and ten revisions (survival rate 70.6%) in the high-risk group. In the low-risk group, six patients (6.5%) showed elevated metal ion levels (> 7 μg/l), compared to five patients (20.8%) in the high risk-group (p = 0.03).

Conclusion: Including the surgeon's initial learning curve, the BHR shows very good mid-term survival rates in the low-risk group but should, as previously demonstrated, not be considered for patients with less than 48 mm femoral head size.

Level of evidence: Level III: retrospective cohort study.

Keywords: ALTR; Hip resurfacing; Magnetic resonance imaging; Metal ion levels.

MeSH terms

  • Arthroplasty, Replacement, Hip* / adverse effects
  • Female
  • Follow-Up Studies
  • Hip Prosthesis*
  • Humans
  • Male
  • Metals
  • Osteoarthritis, Hip* / surgery
  • Prosthesis Design
  • Prosthesis Failure
  • Reoperation
  • Retrospective Studies
  • Surgeons*
  • Treatment Outcome

Substances

  • Metals